US Oncology Reports Fourth Quarter and Fiscal Year 20...(y and financial condition both with resp...)

Date:2/28/2008

y and financial condition, both with respect to the business as a whole and with respect to individual sites in the US Oncology network. Adjusted EBITDA is useful to investors as it eliminates certain amounts that are unusual in nature and not currently expected to be part of the Company's ongoing operational performance. The Company's senior secured credit facility also requires that it comply on a quarterly basis with certain financial covenants that include Adjusted EBITDA as a financial measure. Management believes that EBITDA and Adjusted EBITDA are useful to investors, since they provide investors with additional information that is not directly available in a GAAP presentation.

As a non-GAAP measure, EBITDA and Adjusted EBITDA should not be viewed as alternatives to the Company's GAAP financial statements, but should be read as a supplement to, and in conjunction with, the Company's GAAP financial statements.

US ONCOLOGY HOLDINGS, INC.

KEY OPERATING STATISTICS

(unaudited)

Q4 Q4 % Q3 % Fiscal Fiscal %

2007 2006 Change 2007 Change 2007 2006 Change

Physician

Summary:

Medical

oncologists 705 686 2.8% 714 (1.3)% 705 686 2.8%

Radiation

oncologists 146 146 - 149 (2.0) 146 146 -

Other

oncologists 52 47 10.6 52 - 52 47 10.6

Total CSA

physicians 903 879 2.7 915 (1.3) 903 879 2.7

OPS

physicians 296 188 57.4 249 18.9 296 188 57.4

Total

physicians 1,199 1,067 12.4 1,164 3.0 1,199 1,067 12.4

Daily

Operating

Statistics:

Medical

oncology

visits (1) 10,224 9,918 3.1 10,045 1.8 10,02
'/>"/>

SOURCE US Oncology Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement